First-in-human trial of HemaXellerate-I in patients with bone marrow suppression
Phase of Trial: Phase I/II
Latest Information Update: 24 Oct 2016
At a glance
- Drugs HemaXellerate I (Primary)
- Indications Bone marrow disorders
- Focus Adverse reactions; First in man; Proof of concept
- 24 Oct 2016 Final clinical data on their first 5 patients published in Regen BioPharma media release.
- 16 Aug 2016 Updated interim results (n=5) published in a Regen BioPharma Inc media release.
- 11 May 2016 According to Regen media release, the Company intends to amend its previously submitted Investigational New Drug Application for HemaXellerate in order that Regen may obtain consent from the United States Food and Drug Administration (FDA) to pursue this trial.